Management of Multifocal Lung Cancer: Results of a Survey
Konstantinos Leventakos(Rutgers, The State University of New Jersey), Aaron S. Mansfield(Mayo Clinic), Stephen J. Murphy(Mayo Clinic), Mark S. Allen(Institut für Sozialforschung und Sozialwirtschaft), George Vasmatzis(Mayo Clinic), Tobias Peikert(Mayo Clinic), Julian R. Molina, Christopher L. Hallemeier(Mayo Clinic in Arizona), John J. Mullon(Mayo Clinic in Arizona), Randolph S. Marks(Mayo Clinic), David E. Midthun(Mayo Clinic), Stephen D. Cassivi(Mayo Clinic), Shanda H. Blackmon(The University of Texas MD Anderson Cancer Center), Dennis A. Wigle(Mayo Clinic), Ping Yang(Milken Institute), Yolanda I. Garces(Mayo Clinic), Charles F. Thomas(Mayo Clinic), Eric S. Edell(Mayo Clinic), Marie Christine Aubry(Mayo Clinic), William P. Holland(Mayo Clinic), Francis C. Nichols(Mayo Clinic), Sarah Kratz(Mayo Clinic), Alex A. Adjei(Cleveland Clinic), K. Robert Shen
Cited by 44
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723